Posted on 23/09/2009 in Pharmaceutical Company Product News Recordati has unveiled the findings of a phase III clinical trial into pitavastatin, which revealed that the drug is a valid and effective long-term treatment option for patients with primary hypercholesterolaemia or combined dyslipidaemia.
The outcome also discovered that pitavastatin is non-inferior to first-line treatments atorvastatin and simvastatin and demonstrates sustained efficacy and tolerability over a 52-week period.
Dr Leiv Ose, an investigator of the trial, said: "Many patients do not reach LDL-C (low density lipoprotein cholesterol targets) with current therapies due to a number of factors, especially non-compliance, and a statin which has the potential to improve long-term treatment is welcomed."
Pitavastatin received FDA approval for the primary treatment of hypercholesterolemia and combined dyslipidemia in August and is expected to launch in the US early next year.
In other Recordati news, the firm announced its financial results for the first half of 2009 during the summer and revealed that its revenues reached 379.3 million euros (324.8 million pounds).
Other news stories from 23/09/2009
Read more in the Zenopa News Archive
How this news is generated
|
